GlassScriptPhysician profile
Saadat Aleem
NPI 1033642863
$3,497.25
in general payments reported to CMS, 2019-2025
17 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.10 · 2023: $1,916 · 2024: $898 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393 · Travel and Lodging: $1,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,393.02 |
| Travel and Lodging | $1,092.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,255.34 | 2023 | Linq II |
| Abbott Laboratories | $650.40 | 2023-2024 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| E.R. Squibb & Sons, L.L.C. | $506.36 | 2023-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $307.87 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $248.82 | 2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $149.05 | 2025 | Lokelma, Farxiga |
| Amgen INC. | $128.96 | 2024-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $47.68 | 2024 | Arcalyst |
| Janssen Biotech, INC. | $35.00 | 2025 | Tremfya, Simponi Aria |
| Merck Sharp & Dohme LLC | $34.93 | 2023 | Verquvo, Belsomra |
| Biotronik INC. | $28.24 | 2025 | Amvia Edge |
| Heartflow, INC. | $24.71 | 2025 | |
| Exact Sciences Corporation | $21.87 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $15.89 | 2025 | Watchman Flx |
| Philips North America LLC | $15.80 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2024 | Jardiance |
| Pfizer INC. | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saadat Aleem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.